We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





Longhorn Vaccines and Cenetron Diagnostics Join Coca-Cola Bottlers to Produce COVID-19 Test Kits

By LabMedica International staff writers
Posted on 02 Jun 2020
Longhorn Vaccines and Diagnostics LLC (Bethesda, MD, USA) and Cenetron Diagnostics (Austin, TX, USA) have collaborated with Southeastern Container (SEC) to expand production of COVID-19 testing kits.

SEC is a co-operative funded and managed by a group of independent Coca-Cola bottlers serving the US and Canada. More...
As part of the collaboration, Cenetron and other medical product manufacturers will begin producing COVID-19 testing kits using Longhorn’s proprietary PrimeStore Molecular Transport Medium (MTM) and preform Coca-Cola bottles, sourced from SEC, as test tubes. The goal is to manufacture 1-2 million preform test tubes per week to help meet the broader US testing goal of performing 10 million COVID-19 tests per week.

Longhorn’s PrimeStore MTM is the only FDA cleared nucleic transport device that inactivates microbes within the device. By CDC guidelines, inactivated samples can be transferred to point of care devices and laboratory based molecular testing equipment without the need for a biological safety cabinet, reducing the time from collection to results. Samples can be easily and quickly moved from the Coca-Cola preform to microcentrifuge tubes for rapid automation.

“We are very thankful for the top notch team of problem solvers in the Diagnostic Group at HHS, and the scientists at Oak Ridge and Sandia Laboratories for facilitating this solution through Coke Consolidated, SEC Containers and Berry Global,” said Jeff Fischer, President of Longhorn. “Cenetron and our growing network of manufacturing partners, many of which are small, family owned business, have stepped up to provide much needed filling capacity while providing additional jobs to their communities. These first-rate Coca-Cola preforms, with leak proof caps, will ensure that we can continue to produce as many PrimeStore MTM sample collection devices as the country needs.”

“When the request came for Cenetron to produce millions of PrimeStore MTM tubes, our team had to quickly put all of our resources into setting up and designing systems that allowed us to scale up the project, all while working to keep our employees as safe as possible,” said Brandon Harper, Cenetron’s Chief Operating Officer. “We realize that we must continue to innovate in order to keep our pharma customers, and ultimately patients, safe and moving forward.”

Related Links:
Longhorn Vaccines and Diagnostics LLC
Cenetron Diagnostics



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Blood proteins measured years before diagnosis may signal future prostate cancer risk, including aggressive disease.(Image Credit: iStock)

Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis

Prostate cancer is the most commonly diagnosed cancer in men worldwide. While many tumors grow slowly, aggressive forms can be life-threatening, underscoring the need for earlier risk identification.... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.